Table 2. Correlations between marker expressions and clinicopathological variables with stromal PDGFRα, PDGFRβ, αSMA and vimentin (chi-square and Fisher's exact tests).
PDGFRα S | PDGFRβ S | αSMA | Vimentin | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Low | High | P | Low | High | P | Low | High | P | Low | High | P | |
Age | 0.431 | 0.443 | 0.341 | 0.594 | ||||||||
<65 | 146 | 68 | 124 | 90 | 148 | 79 | 100 | 35 | ||||
≥65 | 207 | 81 | 176 | 109 | 214 | 94 | 133 | 55 | ||||
Gender | 0.225 | 1.000 | 0.138 | 0.331 | ||||||||
Female | 109 | 55 | 97 | 64 | 123 | 47 | 51 | 25 | ||||
Male | 244 | 94 | 203 | 135 | 239 | 126 | 182 | 65 | ||||
Weight-loss | 0.659 | 0.119 | 0.602 | 0.808 | ||||||||
<10% | 319 | 132 | 275 | 173 | 327 | 153 | 211 | 80 | ||||
>10% | 34 | 17 | 25 | 26 | 35 | 20 | 22 | 10 | ||||
Smoking status | 0.842 | 0.100 | 0.726 | 0.041 | ||||||||
Never | 10 | 4 | 12 | 2 | 10 | 7 | 13 | 0 | ||||
Present | 222 | 98 | 184 | 132 | 233 | 109 | 146 | 63 | ||||
Previous | 121 | 47 | 104 | 65 | 119 | 57 | 74 | 27 | ||||
ECOG | 0.756 | 0.003 | 0.704 | 0.860 | ||||||||
Normal | 203 | 91 | 193 | 98 | 211 | 98 | 136 | 51 | ||||
Slightly | 125 | 48 | 91 | 82 | 125 | 65 | 85 | 33 | ||||
In bed<50% | 25 | 10 | 16 | 19 | 26 | 10 | 12 | 6 | ||||
Histology | 0.069 | 0.093 | 0.393 | 0.303 | ||||||||
SCC | 190 | 83 | 152 | 120 | 198 | 90 | 137 | 53 | ||||
ADC | 127 | 60 | 124 | 64 | 137 | 64 | 77 | 25 | ||||
NOS | 36 | 6 | 24 | 15 | 27 | 19 | 19 | 12 | ||||
T-stage | 0.159 | 0.840 | 0.505 | 0.888 | ||||||||
T1a | 49 | 22 | 45 | 26 | 53 | 21 | 25 | 11 | ||||
T1b | 68 | 20 | 54 | 34 | 63 | 31 | 42 | 15 | ||||
T2a | 127 | 49 | 101 | 71 | 128 | 61 | 86 | 36 | ||||
T2b | 42 | 29 | 46 | 25 | 48 | 27 | 33 | 14 | ||||
T3 | 64 | 26 | 51 | 40 | 68 | 29 | 47 | 14 | ||||
T4 | 3 | 3 | 3 | 3 | 2 | 4 | 0 | 0 | ||||
N-stage | 0.273 | 0.911 | 0.541 | 0.227 | ||||||||
N0 | 237 | 105 | 202 | 136 | 248 | 116 | 159 | 64 | ||||
N1 | 85 | 27 | 68 | 42 | 75 | 42 | 58 | 16 | ||||
N2 | 31 | 17 | 30 | 21 | 39 | 15 | 16 | 10 | ||||
P-stage | 0.769 | 0.938 | 0.875 | 0.954 | ||||||||
IA | 93 | 34 | 79 | 47 | 94 | 40 | 53 | 21 | ||||
IB | 79 | 33 | 67 | 43 | 81 | 41 | 52 | 23 | ||||
IIA | 82 | 32 | 65 | 45 | 76 | 42 | 63 | 21 | ||||
IIB | 48 | 23 | 43 | 29 | 51 | 24 | 35 | 14 | ||||
IIIA | 51 | 27 | 46 | 35 | 60 | 26 | 30 | 11 | ||||
Differentiation | 0.129 | 0.250 | 0.688 | 0.917 | ||||||||
Poor | 153 | 59 | 131 | 78 | 160 | 70 | 98 | 39 | ||||
Moderate | 152 | 77 | 138 | 91 | 158 | 82 | 104 | 38 | ||||
Well | 48 | 13 | 31 | 30 | 44 | 21 | 31 | 13 | ||||
Vascular invasion | 0.520 | 0.906 | 0.012 | 0.236 | ||||||||
No | 292 | 119 | 244 | 163 | 306 | 130 | 200 | 72 | ||||
Yes | 60 | 29 | 55 | 35 | 55 | 42 | 33 | 18 |
Abbreviations: PDGFR, platelet derived growth factor; αSMA, alpha-smooth muscle actin; S, stroma; ECOG, Eastern cooperative oncology group; SCC, squamous cell carcinoma; ADC, adenocarcinoma; NOS, not otherwise specified